PA Inhibitors
PA inhibitors are a class of chemical compounds designed to target phosphatidic acid (PA), a key phospholipid intermediate involved in multiple cellular processes, including membrane biosynthesis and signal transduction. Phosphatidic acid is generated through the phosphorylation of diacylglycerol (DAG) by diacylglycerol kinase or by the hydrolysis of phosphatidylcholine through phospholipase D activity. PA acts as a precursor for the synthesis of other phospholipids, such as phosphatidylserine, phosphatidylethanolamine, and phosphatidylcholine, which are essential components of cell membranes. It also plays a critical role in lipid signaling pathways by serving as a second messenger, regulating proteins involved in cell growth, vesicle trafficking, and cytoskeletal dynamics. PA inhibitors disrupt these pathways by interfering with the production, function, or localization of phosphatidic acid within the cell.
PA inhibitors may target enzymes involved in PA synthesis, such as phospholipase D or diacylglycerol kinase, or they may bind directly to PA molecules, blocking their interaction with downstream signaling proteins. These inhibitors often work by either mimicking the structure of PA or competing with its binding partners, thereby preventing its ability to act as a signaling molecule or precursor for membrane phospholipids. Researchers utilize PA inhibitors to explore the various roles that PA plays in cellular processes, from membrane curvature and vesicle formation to the regulation of kinases and phosphatases involved in cell signaling. By inhibiting PA, scientists gain insights into how lipid signaling impacts fundamental processes such as cell division, motility, and stress response. These studies help reveal the complexities of lipid-mediated communication within cells and the broader role of PA in maintaining cellular homeostasis.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib (CAS 179324-69-7) is a boronic acid dipeptide and potent inhibitor of the proteasome, specifically interacting with the PA protein to disrupt its activity. Its mechanism of action involves the reversible binding of its boronic acid group to the active site of the proteasome, leading to inhibition of proteolysis. This disruption of protein degradation pathways has been studied extensively in various research applications related to protein turnover and cellular regulation. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib (CAS 868540-17-4) is a potent and selective inhibitor of the PA protein, targeting its proteolytic activity. It binds irreversibly to the catalytic sites, disrupting protein degradation pathways by inhibiting the proteasome function. This inhibition impedes the protein breakdown process, offering researchers a valuable tool for studying proteasome-related mechanisms in cellular regulation and protein homeostasis. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib (CAS 1072833-77-2) is a selective inhibitor of the PA protein, functioning by disrupting the protein′s proteasomal degradation pathway. This inhibition affects protein homeostasis and cellular mechanisms related to protein turnover. Researchers use ixazomib to study proteasome dynamics, protein-protein interactions, and regulatory pathways involving proteostasis, making it valuable for understanding proteasome-related mechanisms at the molecular level. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib (CAS 935888-69-0) is a selective inhibitor of the PA protein, specifically targeting proteasomal activity by binding to its catalytic subunits. This inhibition disrupts the protein degradation process, which is crucial in various cellular mechanisms. Oprozomib′s ability to block PA activity makes it useful in scientific studies investigating protein homeostasis and related cellular functions. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib, free base, is a potent inhibitor of the PA protein, involved in disrupting the PA subunit′s activity in proteasome assembly. By binding to the PA protein, Delanzomib interferes with its normal function, impacting protein degradation pathways. This makes it a valuable tool for studying protein homeostasis and regulatory mechanisms related to the proteasome system in scientific research. | ||||||